The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.
October 2nd 2024
The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!
Zilebesiran, an RNA Interference Agent, Shows Promise for Hypertension in Phase 1 Trial
July 24th 2023A multipart, phase 1 trial provides evidence demonstrating the safety of zilebesiran, an RNA interference agent, which appeared to have a favorable safety profile among adult patients with hypertension.
AHA Highlights Pediatric Hypertension in Scientific Statement
March 30th 2023The latest scientific statement from the American Heart Association takes aim at offering clinicians with a summary of contemporary evidence related to the prevalence and increase in long-term risk associated with hypertension in children and adolescents.
Increased BMI in Childhood Increases Hypertension Risk as an Adult
March 14th 2023An analysis of more than 800,000 children with more than 3.5 million person-years of follow-up indicate those in the upper range of average BMI had a 26% greater risk of developing hypertension, with each per unit increase in BMI associated with a 4% increase in risk of hypertension.
STELLAR: Sotatercept Improves Function, Alleviates Disease Burden in Pulmonary Arterial Hypertension
March 6th 2023Data from the phase 3 STELLAR trial indicate adding sotatercept to background therapy in PAH was associated with statistically significant improvements in 6-minute walk distance and 8 of the trial's 9 secondary endpoints, including time to death or clinical worsening.
Gluconic Acid Could Serve as Race-Specific Biomarker for Hypertension and Stroke Risk
February 2nd 2023A study presented at the International Stroke Conference 2023 suggests the plasma metabolite gluconic acid could serve as a race-specific biomarker for identifying increased risk of hypertension and stroke in Black adults.
Impact of Traditional Stroke Risk Factors on Stroke Risk Lessens Over Time, Study Finds
January 19th 2023An analysis of patient data from the REGARDS cohort suggests the increase in relative risk observed with traditional risk factors, such as hypertension and diabetes, on risk of stroke decreases as patients age, but investigators point out this does not diminish the importance of addressing these risk factors.
Noninvasive CT Scan Could Identify Primary Aldosteronism Patients Eligible for Adrenalectomy
January 17th 2023Comparing MTO scanning against adrenal vein sampling, investigators in the UK found the noninvasive diagnostic option could improve the identification of primary aldosteronism and candidates for adrenalectomy.
Mediterranean Diet Linked to Reduce Risk of Adverse Pregnancy Outcomes in Nulliparous Women
December 23rd 2022Data from the nuMoM2b study suggests greater adherence to a Mediterranean diet was associated with reductions of 37%, 28%, and 21% in odds of gestational diabetes, preeclampsia, and any adverse pregnancy outcome, respectively, among a cohort of more than 7000 nulliparous women.
Excessive Coffee Consumption Could Spell Disaster for People with Hypertension
December 21st 2022An analysis of data from the Japanese Collaborative Cohort Study for Evaluation of Cancer Risk suggests those with grade 2-3 hypertension could be increasing their risk of cardiovascular death by consuming 2 or more cups of coffee per day.
Many Cases of New-Onset Postpartum Hypertension Go Unnoticed for Weeks
November 15th 2022An analysis of data from deliveries occurring at a large, urban medical center in Boston from 2016-2018 suggests more than 10% of women with no history of hypertension developed hypertension within a year after delivery.
Study Proves Feasibility of Entirely Remote Management of Hypertension, Cholesterol Disorders
November 10th 2022A 10,000-person study provides insight into the feasibility and effectiveness of participation an entirely remote hypertension and lipid management program in a diverse health care network.
Phase 2 Data Shows Promise for Baxdrostat in Treatment-Resistant Hypertension
November 7th 2022Phase 2 data from the BrigHTN trial suggest use of 2 mg baxdrostat was associated with significantly and substantially reduced systolic and diastolic blood pressure in patients with treatment-resistant hypertension. In a Q&A, trial investigator Deepak Bhatt, MD, MPH, provides further insight.